Cancer is a highly individual disease that requires tailored treatment decisions for each patient. At PreComb, we are developing the first fully automated 3DTwin® technology to drive evidence-based therapy prediction for drug discovery and therapy guidance. The 3DTwin® technology allows for efficacy testing of a broad drug portfolio directly in the clinic on patient-derived tumor twins. Together with our clinical partners, we are opening a new era in personalized oncology.